Instalab
logoInstalab

Testosterone Aging Panel

Blood Test
See what's really behind the fatigue, stubborn weight, and low drive, not just whether one testosterone number lands in range.
4.9 (2,784 reviews)
Tested by Quest or Access Medical
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Testosterone Aging Panel test?

This test is most useful if any of these apply to you.

Noticing You've Slowed Down
You're past 40 and your energy, drive, and muscle aren't what they were, and you want to know if hormones are behind it.
Gaining Weight Around the Middle
A thickening waist and rising blood sugar may be feeding low testosterone, and this shows whether metabolism is the real driver.
Considering or On Testosterone
You want a full baseline and the prostate and blood-count safety markers checked before or while you treat low hormones.
Healthy but Staying Ahead
You feel fine and want an early read on how your hormones and metabolism are aging together, well before symptoms start.

16 biomarkers included

About Testosterone Aging Panel

Testosterone rarely falls off a cliff. It drifts down slowly over decades, and the symptoms it causes, low energy, softening muscle, a thickening waist, and flagging drive, look almost identical to ordinary aging. That overlap is exactly why a single testosterone number so often misleads.

This panel reads three connected systems in one morning draw: the hormone loop that makes and regulates testosterone, the metabolic machinery that both drives and responds to it, and the safety markers that matter the moment treatment enters the conversation.

What This Panel Reveals

How Much Active Hormone You Actually Have

Most of your testosterone travels stuck to a carrier protein and is not available to your tissues. This panel measures total testosterone, the free (unbound, usable) fraction, and the carrier protein itself, called sex hormone binding globulin (SHBG). Reading them together matters because SHBG climbs with age. As it rises, more of your testosterone gets locked away, so the free portion can drop years before the total number ever looks low.

The gap is real. In healthy aging men, total testosterone falls slowly, while free testosterone drops roughly one to two percent per year, driven largely by rising SHBG. Free testosterone often tells the truer story of what your body is experiencing.

Where the Problem Sits in the Loop

Your brain drives the testes through two pituitary signals: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Measuring them turns a vague low reading into a located one. When testosterone is low and these signals are high, the testes are struggling and the brain is shouting louder to compensate, a mostly age-related pattern. When testosterone is low but the signals are low or normal, the problem sits higher up, in the brain, and is often tied to obesity or metabolic illness.

Estradiol, the estrogen your body makes from testosterone, rounds out the picture. Some symptoms blamed on low testosterone, including bone loss and reduced sexual function, partly reflect low estrogen. It also helps explain the feedback signals the pituitary is sending.

The Metabolic Half of the Story

Low testosterone and metabolic trouble feed each other. Belly fat lowers testosterone, and low testosterone encourages more belly fat and insulin resistance. That is why this panel pairs the hormones with blood sugar (glucose and HbA1c, a three-month blood sugar average), fasting insulin, and a full cholesterol breakdown. In one clinic study, 43 percent of men with type 2 diabetes had low total testosterone.

The lipid and sugar markers do double duty. They flag cardiovascular and diabetes risk on their own, and they reveal whether a low testosterone reading is being driven by reversible metabolic problems rather than true hormonal failure. Low testosterone commonly travels with high triglycerides and low HDL cholesterol.

The Safety Markers

Two tests here exist mainly to protect you if treatment is ever considered. Hematocrit, the share of your blood made of red cells, can climb on testosterone therapy; in a pooled analysis of trials, treated men were nearly four times as likely to push hematocrit above 50 percent, making it the most common side effect. Total PSA (prostate-specific antigen, a prostate protein) is the prostate surveillance marker guidelines want checked before and during therapy.

How to Read Your Results Together

No single value settles this. The value comes from the pattern across the hormones, the binding protein, and the metabolic markers. A few combinations do most of the interpretive work:

PatternWhat it suggests
Low total and low free testosterone, with high LH and FSHPrimary testicular decline, the classic aging pattern with the most consistent symptoms
Normal total testosterone but low free testosterone, with high SHBGAge-related deficiency hidden by a high carrier protein; the free number is the honest one
Low total testosterone, normal free testosterone, low SHBG, normal LHOften obesity-related rather than true gonadal failure, and frequently without classic symptoms
Low testosterone alongside high triglycerides, low HDL, and rising glucose or HbA1cMetabolically driven; weight and insulin resistance are likely the lever to pull first

One reading is never enough. About 30 percent of men whose first testosterone falls in the low range test normal on a repeat, so a low result is a reason to retest, not a diagnosis.

What to Do with Your Results

Start with the hormone pattern. If total testosterone sits near the lower limit or your SHBG is high or low, the free testosterone number should anchor your read. A confirmed low value, drawn fasting in the morning on two separate days, alongside real symptoms is what points toward genuine deficiency worth acting on.

Let the split guide the next step. A high-LH, high-FSH pattern points toward the testes and warrants a conversation with a urologist or endocrinologist. A low-signal pattern with a large waist and abnormal sugar points toward metabolic causes, where weight loss and insulin sensitivity often lift testosterone without hormones at all. Adding a marker of inflammation and a formal insulin resistance calculation sharpens that read.

If treatment is on the table, the safety markers set the guardrails. Guidelines advise against starting therapy with a PSA above 4 ng/mL, or above 3 ng/mL in higher-risk men without urologic evaluation, or with an already elevated hematocrit. Retesting every 6 to 12 months lets you track whether a change in hormones, weight, or medication is moving the numbers the direction you intended.

When Results Can Be Misleading

Timing is the biggest trap. Testosterone peaks in the morning and drops through the day; in men in their thirties, afternoon levels run 20 to 25 percent lower than morning levels, so an afternoon draw can invent a problem that a morning draw erases. Food lowers it too, which is why a fasting morning sample is the standard.

Acute illness, poor sleep, and short courses of certain medications can all temporarily suppress testosterone. And because obesity and diabetes push the carrier protein down, they can drag total testosterone below range while your usable free testosterone stays normal. That is the whole reason this panel measures the binding protein and the metabolic markers instead of a lone testosterone value.

Frequently Asked Questions

References

12 studies
  1. S. Bhasin, J. Brito, G. Cunningham, F. Hayes, H. Hodis, a. Matsumoto, P. Snyder, R. Swerdloff, Frederick C W Wu, Maria a. YialamasThe Journal of Clinical Endocrinology and Metabolism2018
  2. Frederick C W Wu, a. Tajar, J. Beynon, S. Pye, a. Silman, J. Finn, T. O'neillThe New England Journal of Medicine2010
  3. A. Tajar, G. Forti, T. O'neill, David M Lee, a. Silman, J. FinnThe Journal of Clinical Endocrinology and Metabolism2010
  4. L. Antonio, Frederick C. W. Wu, T. O'neill, S. Pye, T. Ahern, Michaël R. LaurentThe Journal of Clinical Endocrinology and Metabolism2016
  5. A. Tajar, I. Huhtaniemi, T. O'neill, J. Finn, S. Pye, David M LeeThe Journal of Clinical Endocrinology and Metabolism2012